Virtus Fund Advisers’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Virtus Fund Advisers’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$980K	Buy	+18,171	New	+$994K	0.01%	293

Other funds holding BIVV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Virtus Fund Advisers's BIVV Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Bioverativ Inc. Common Stock (BIVV) in Q4 2017: 18,171 shares worth $980K. The stake represents 0.01% of the portfolio and ranks #293 among its holdings.

459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

Virtus Fund Advisers held 18,171 shares of Bioverativ Inc. Common Stock worth $980K as of Q4 2017.
Bioverativ Inc. Common Stock was a new Virtus Fund Advisers position in Q4 2017.
Bioverativ Inc. Common Stock made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #293 holding.
459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.